$Zai Lab Ltd(ZLAB)$ just dropped some crazy data at ASCO，their ZL-1310 showed a 79% ORR in second-line small cell lung cancer. That’s not just “good,” that’s holy sht, pay attention* level, especially in SCLC. What’s funny is, people are still stuck on “can they out-license it?” I think they’re missing the real story，Zai might be going all in to build something global here. This feels more like “we’re done being a junior partner, time to lead.”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
